| 7.37 -0.14 (-1.86%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.25 | 1-year : | 10.8 |
| Resists | First : | 7.92 | Second : | 9.25 |
| Pivot price | 7.36  |
|||
| Supports | First : | 6.57 | Second : | 5.73 |
| MAs | MA(5) : | 7.45  |
MA(20) : | 7.17 |
| MA(100) : | 5.7 |
MA(250) : | 0 | |
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 67.3 |
D(3) : | 70.3 |
| RSI | RSI(14): 56.9 |
|||
| 52-week | High : | 7.96 | Low : | 3.75 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PROF ] has closed below upper band by 49.7%. Bollinger Bands are 11.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.51 - 7.55 | 7.55 - 7.59 |
| Low: | 7.19 - 7.24 | 7.24 - 7.28 |
| Close: | 7.3 - 7.38 | 7.38 - 7.45 |
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Wed, 24 Dec 2025
Profound Medical Corp. Announces Upsize of Private Placement - Yahoo Finance
Tue, 23 Dec 2025
How Profound Medical plans to use its new $36M cash infusion - Stock Titan
Fri, 28 Nov 2025
Profound Medical Corp Launches TULSA-AI Volume Reduction Module - TradingView — Track All Markets
Sat, 15 Nov 2025
Profound Medical Corp. (NASDAQ:PROF) Q3 2025 Earnings Call Transcript - Insider Monkey
Thu, 13 Nov 2025
Profound Medical Reports Strong Third Quarter 2025 Financial Results - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 30 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 17.2 (%) |
| Held by Institutions | 41 (%) |
| Shares Short | 1,100 (K) |
| Shares Short P.Month | 893 (K) |
| EPS | -1.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.07 |
| Profit Margin | -275.2 % |
| Operating Margin | -168.6 % |
| Return on Assets (ttm) | -62.5 % |
| Return on Equity (ttm) | -124.5 % |
| Qtrly Rev. Growth | 86.8 % |
| Gross Profit (p.s.) | 0.34 |
| Sales Per Share | 0.47 |
| EBITDA (p.s.) | -1.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -38 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -5.59 |
| PEG Ratio | 0 |
| Price to Book value | 6.88 |
| Price to Sales | 15.55 |
| Price to Cash Flow | -5.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|